In today’s briefing:
- Anthem Biosciences IPO Trading – Robust Insti Coverage Drives Overall Demand
- Shoulder Innovations, Inc. (SI): Peeking at the Prospectus of Another MedTech IPO
Anthem Biosciences IPO Trading – Robust Insti Coverage Drives Overall Demand
- Anthem Biosciences (1234D IN) raised about US$397m in its India IPO.
- Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
- We have looked at the company’s past performance in our previous notes. In this note, we will talk about the peer comp and IPO valuations.
Shoulder Innovations, Inc. (SI): Peeking at the Prospectus of Another MedTech IPO
- They are a commercial stage medical technology company that currently offers advanced implant systems for shoulder arthroplasty.
- They generated net revenue of $31.6 million for the year ended December 31, 2024, compared to net revenue of $19.3 million for the year ended December 31, 2023 (64% growth).
- This IPO could set terms as early as next week for a late July or early August debut.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
